Dr Reddys Laboratories' Q2 FY 2025-26 Quarterly Results
- 11h ago
Result Summary
- Dr Reddys Laboratories Ltd reported a 3.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.7%.
- Its expenses for the quarter were up by 6.6% QoQ and 15.2% YoY.
- The net profit decreased 5.2% QoQ and decreased 0.4% YoY.
- The earnings per share (EPS) of Dr Reddys Laboratories Ltd stood at 16.17 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
| (₹ crores) | Q2FY26 | Q1FY26 | Q2FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 9152.20 | 8862.40 | 8345.70 | 3.3% | 9.7% |
Total Expenses | 7413.70 | 6957.60 | 6434.40 | 6.6% | 15.2% |
Profit Before Tax | 1738.50 | 1904.80 | 1911.30 | -8.7% | -9.0% |
Tax | 408.00 | 495.10 | 575.50 | -17.6% | -29.1% |
Profit After Tax | 1336.80 | 1409.90 | 1341.90 | -5.2% | -0.4% |
Earnings Per Share | 16.17 | 17.02 | 80.45 | -5.0% | -79.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr. Reddy's Laboratories Ltd is a prominent pharmaceutical company based in India, known for manufacturing and marketing a wide range of pharmaceutical products. The company operates in various segments including Active Pharmaceutical Ingredients (APIs), generics, biosimilars, and proprietary products. Dr. Reddy's serves markets across the globe, with a strong presence in the United States, India, Russia, and other international markets. They focus on providing affordable and innovative medicines to patients worldwide. Recent major developments regarding the company are not provided in the data.
Revenue
In Q2FY26, Dr. Reddy's Laboratories Ltd reported a total income of ₹9152.20 crores. This represents a quarter-over-quarter (QoQ) increase of 3.3% compared to ₹8862.40 crores in Q1FY26 and a year-over-year (YoY) growth of 9.7% from ₹8345.70 crores in Q2FY25. The revenue growth indicates a steady increase in income from the previous fiscal periods, reflecting the company's ability to generate more sales or possibly higher pricing of its products within the market.
Profitability
The company recorded a Profit Before Tax (PBT) of ₹1738.50 crores in Q2FY26, which is a decrease of 8.7% QoQ from ₹1904.80 crores in Q1FY26, and a 9.0% decline YoY from ₹1911.30 crores in Q2FY25. The Profit After Tax (PAT) for Q2FY26 was ₹1336.80 crores, down by 5.2% QoQ from ₹1409.90 crores in Q1FY26 and slightly lower by 0.4% YoY compared to ₹1341.90 crores in Q2FY25. Earnings Per Share (EPS) stood at ₹16.17 in Q2FY26, marking a 5.0% decrease QoQ from ₹17.02 and a significant YoY drop of 79.9% from ₹80.45. These profitability metrics reflect variations in the company's financial outcomes over the periods in question.
Operating Metrics
Total expenses for Dr. Reddy's Laboratories in Q2FY26 amounted to ₹7413.70 crores, which increased by 6.6% QoQ from ₹6957.60 crores in Q1FY26 and rose by 15.2% YoY from ₹6434.40 crores in Q2FY25. The tax paid during Q2FY26 was ₹408.00 crores, representing a reduction of 17.6% QoQ from ₹495.10 crores in Q1FY26 and a YoY decrease of 29.1% from ₹575.50 crores in Q2FY25. These figures indicate changes in the company’s expenditures and tax liabilities over the respective quarters and years. The provided data does not include additional information necessary to calculate further financial ratios such as P/E ratio, debt-to-equity ratio, or current ratio.
FAQs
When was Dr Reddys Laboratories Ltd Q2 FY 2025-26 result announced?
Dr Reddys Laboratories Ltd announced its Q2 FY 2025-26 results on 25 October, 2025.
What are Dr Reddys Laboratories Ltd quarterly results?
Dr Reddys Laboratories Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Dr Reddys Laboratories Ltd Q2 FY 2025-26 results?
Key highlights of Dr Reddys Laboratories Ltd Q2 FY 2025-26 results include:
- Revenue: ₹9152.20 crore
- Net Profit: ₹1336.80 crore
- EBITDA: ₹2333.80 crore
- Year-over-Year Growth: 9.7%
- Quarter-over-Quarter Growth: 3.3%
How did Dr Reddys Laboratories Ltd net profit perform in this quarter?
Dr Reddys Laboratories Ltd reported a net loss of ₹1336.80 crore in Q2 FY 2025-26, reflecting a -0.4% year-over-year growth.
What was Dr Reddys Laboratories Ltd revenue in Q2 FY 2025-26?
Dr Reddys Laboratories Ltd posted a revenue of ₹9152.20 crore in Q2 FY 2025-26.